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Abstract 
Background: Stereotactic body radiation therapy (SBRT) is an established therapy for medically inoperable early-
stage non-small cell lung cancer (NSCLC). Many elderly patients are medically inoperable owing to comorbidi-
ties. Therefore, SBRT may be a useful therapy for elderly patients. However, the application of SBRT for patients 
aged ≥ 80 years has not been completely elucidated. Therefore, this study aimed to assess the clinical utility of SBRT 
for elderly patients aged ≥ 80 years with pathologically proven early-stage NSCLC.
Methods: We retrospectively evaluated the data of patients aged ≥ 80 years with pathologically proven primary 
NSCLC who underwent SBRT at our institution between January 2009 and March 2020. Treatment outcomes and tox-
icities were analyzed. We used the Kaplan–Meier method to estimate survival curves and the log-rank test to compare 
the survival curves. We performed univariate and multivariate Cox regression analyses. p-values < 0.05 were regarded 
significant.
Results: Sixty-four patients (65 lesions) were included, and the median follow-up period was 38.7 (range 3.5–95.7) 
months. The median age was 82.9 (range 80.0–94.8) years. Sixteen patients were medically operable, and 48 patients 
were medically inoperable. The prescribed dose of SBRT was either 48 Gy in four fractions or 60 Gy in 10 fractions. The 
median survival time was 60.0 months (95% confidence interval, 43.5–71.1). The 1-, 3-, and 5-year local control, cancer-
specific survival, progression-free survival, and overall survival rates were 98.4%, 98.4%, 81.0%, and 88.9%; 90.1%, 
93.7%, 58.9%, and 68.3%; and 87.4%, 83.5%, 38.2%, and 47.5%, respectively. Multivariate analysis revealed that inoper-
ability and solid nodules were the predictors of poor overall survival after SBRT in elderly patients. Two patients (3.1%) 
had grade 3 radiation pneumonitis, and one patient (1.6%) had grade 5 radiation pneumonitis.
Conclusions: SBRT was feasible in patients aged ≥ 80 years with NSCLC. It achieved good local control with minimal 
toxicity. SBRT may be beneficial in elderly patients with early-stage NSCLC.
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Background
Primary lung cancer is one of the common life-threaten-
ing malignancies and is the main cause of death among 
all cancers [1]. The proportion of elderly patients with 
primary lung cancer is predicted to increase owing to 
the aging of the general population [2, 3]. Therefore, the 
treatment strategy for elderly patients with primary lung 
cancer is an important consideration.
Surgery is the standard treatment for early-stage non-
small cell lung cancer (NSCLC) [4]. However, no evi-
dence-based standard treatments for elderly patients 
with NSCLC exist, particularly for those aged ≥ 80 years. 
Although surgical resection is an effective treatment 
for elderly patients [5], it is often not feasible in elderly 
patients aged ≥ 80 years owing to comorbidities.
Stereotactic body radiation therapy (SBRT) is the usual 
treatment for medically inoperable patients, and it pro-
vides good local control rates and induces minimal toxic-
ity [6–11]. Therefore, SBRT may be beneficial in elderly 
patients. According to a national survey in South Korea, 
the percentage of patients aged ≥ 80 years receiving SBRT 
as a treatment modality for early NSCLC increased from 
9.4% in 2008 to 28.6% in 2016 [12]. While some studies 
have revealed that SBRT is an effective and safe treatment 
modality in elderly patients aged ≥ 80  years [13–15], 
most studies included patients who were not pathologi-
cally confirmed to have NSCLC.
Pulmonary nodules may be benign (e.g., organized 
pneumonia, tuberculosis, and sclerosing hemangioma) 
[16, 17]. Radiation therapy to treat these infectious nod-
ules or benign lesions is contraindicated. Therefore, it 
is desirable to make a definitive diagnosis before can-
cer treatment. A study reported the outcomes of SBRT 
for patients aged ≥ 75  years with pathologically proven 
early-stage NSCLC [18]. This study revealed that SBRT 
had excellent tumor control rates and low toxicity rates in 
patients aged ≥ 75  years with proven NSCLC. However, 
to the best of our knowledge, with respect to the clinical 
outcome of SBRT, there is no study in which all patients 
aged ≥ 80  years have been pathologically diagnosed to 
have NSCLC. Thus, this study aimed to assess the clinical 
utility of SBRT for elderly patients aged ≥ 80  years with 
pathologically proven early-stage NSCLC.
Methods
Patients
We retrospectively evaluated the data of consecu-
tive patients aged ≥ 80  years at the start of SBRT for 
T1-2N0M0 (tumor-node-metastasis classification, 8th 
edition) primary lung cancer at Okayama University 
Hospital between January 2009 and March 2020. Patients 
without pathologically proven NSCLC were excluded.
Computed tomography (CT) scan was performed for 
all patients to stage their lung cancer. On CT, the lesions 
were classified as ground-glass, part solid, or solid, and 
tumor size was measured including that of ground glass 
lesions. Positron emission tomography, if performed, was 
also used for cancer staging. All tumors were subjected 
to CT-guided or bronchoscope-guided biopsies to con-
firm the pathology. Data related to patients’ pretreatment 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) score and body mass index were col-
lected. The Charlson Comorbidity Index was calculated. 
Global Initiative for Chronic Obstructive Lung Disease 
stage was classified according to the results of the pre-
treatment pulmonary function tests. Board-certified 
thoracic surgeons or respiratory physicians determined 
whether the patients could tolerate surgical resection 
after considering respiratory function, comorbidities, 
possibility of general anesthesia, and general condition. 
Patients who could not tolerate surgery were defined as 
medically inoperable.
Treatment
Long-scan-time non-breath-hold CT was performed to 
delineate the internal target volume after immobilization 
with the Vac-Loc and Hip-Fix systems (CIVCO Medical 
Solutions, Orange City, IA, USA), and compressing the 
chest and abdomen. The respiratory motion was reduced 
by using the aforementioned device and respiratory 
depression. We used X-ray fluoroscopy to evaluate tumor 
motion. The planning target volume (PTV) included the 
internal target volume plus a 5–8-mm margin. A radia-
tion therapy planning system (Xio version 4.8.0; Ele-
kta, Stockholm, Sweden) was used with a superposition 
dose calculation algorithm with heterogeneity correc-
tion. Radiation therapy was delivered using 6-MV pho-
tons from a linear accelerator (Primus; Canon Medical 
Systems, Tochigi, Japan) in multiple coplanar and non-
coplanar static ports. We prescribed 48  Gy in 4 frac-
tions for peripheral lesions and 60 Gy in 10 fractions for 
central lesions or lesions adjacent to the brachial plexus. 
SBRT was performed daily on weekdays. Until October 
31, 2015, the prescribed dose was defined as the dose 
at the isocenter. Subsequently, the prescribed dose was 
defined as the dose covering 95% of the PTV (D95). We 
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evaluated toxicities using the Common Terminology Cri-
teria for Adverse Events (version 5.0) [19]. We collected 
the data on grade ≥ 3 adverse events.
Statistical analysis
We estimated local control (LC), cancer-specific sur-
vival (CSS), progression-free survival (PFS), and over-
all survival (OS) rates using the Kaplan–Meier method 
and compared survival curves using the log-rank test. 
We performed univariate and multivariate Cox regres-
sion analyses to determine if either clinical or treat-
ment-related factors could predict LC, CSS, PFS, or OS. 
Variables with p-values < 0.05 in the univariate analysis 
were retained in the multivariate analysis. We used Stata/
IC 16.1 (StataCorp, College Station, TX, USA) to conduct 




In total, 162 consecutive patients (166 lesions) were 
treated with SBRT at our hospital between January 2009 
and March 2020. Among those patients, 64 patients (65 
lesions; 45 men and 19 women) aged ≥ 80  years with 
pathologically proven NSCLC were included in our 
study. Sixty-three patients had been evaluated using posi-
tron emission tomography-CT before the treatment. The 
median (range) age and ECOG PS were 82.9 (80.0–94.8) 
years and 1 (0–3), respectively. The median (range) fol-
low-up period after SBRT was 38.7 (3.5–95.7) months. 
One patient had synchronous primary lung cancer. No 
patient had interstitial pneumonia before treatment. 
Patient and tumor characteristics are summarized in 
Table 1.
Treatment and disease control
The median survival time was 60.0  months (95% con-
fidence interval, 43.5–71.1). Forty-one patients were 
treated with 48 Gy to the isocenter, six were treated with 
60  Gy to the isocenter, and 18 were treated with 48  Gy 
(D95). The median (range) PTV was 32.4 (9.6–110.6) ml. 
The 1-, 3-, and 5-year LC rates were 98.4%, 90.1%, and 
87.4%, respectively. The 1-, 3-, and 5-year CSS, PFS, and 
OS rates were 98.4%, 93.7%, and 83.5%; 81.0%, 58.9%, 
and 38.2%; and 88.9%, 68.3%, and 47.5%, respectively 
(Table 2 and Fig. 1). The median time to local recurrence 
among the patients who developed local recurrence was 
25.3 months (95% confidence interval, 7.7–38.1).
The OS rates for operable (n = 16) and inoperable 
(n = 48) patients are shown in Fig.  2. The 1-, 3-, and 
5-year OS rates for operable and inoperable patients were 
100.0%, 79.4%, and 79.4%, and 85.4%, 64.7%, and 36.6%, 
respectively, with significant differences in the survival 
curves (log-rank test, p = 0.003).
Univariate analysis did not identify any predictors of 
LC or CSS. However, univariate analysis did identify 
ECOG PS, operability, tumor appearance, and tumor his-
tology as the predictors of PFS [p = 0.035, 0.014, 0.021, 
Table 1 Patient and tumor characteristics
BMI, body mass index; D95, dose covering 95% of the PTV; ECOG, Eastern 
Cooperative Oncology Group; GOLD, Global Initiative for Chronic Obstructive 
Lung Disease; FEV, forced expiratory volume; GGN, ground-glass nodule; ITV, 
internal target volume; NSCLC, non-small cell lung cancer; PS, performance 
status; PTV, planning target volume
† These variables have missing values
Characteristic Value
Age (years), median (range) 83 (80.0–94.8)
Sex (n), male/female 45/19
Follow-up (months), median (range) 39 (3.5–95.7)
BMI (kg/m2), median (range) 22.8 (16.7–29.4)
BMI distribution (n), < 18.5/18.5–25.0/ > 25 kg/m2 5/48/11
ECOG PS (n), 0/1/2/3 28/19/11/6
Operability (n), yes/no 16/48
GOLD stage (n), normal/I/II/III† 24/18/13/4
FEV1.0 (L), median (range) † 1.6 (0.7–2.7)
History of lung operation (n), yes/no 14/50
Charlson Comorbidity Index (n), 2/3/4/5/6/7/9 10/28/12/7/3/2/2
T stage (n), Tis/T1mi/T1a/T1b/T1c/T2a/T2b 2/2/5/26/17/10/3
Maximum tumor diameter (cm), median (range) 2.1 (0.8–4.1)
ITV (mL), median (range) 10.2 (1.1–51.8)
PTV (mL), median (range) 32.4 (9.6–110.6)
Histology (n)
 Adenocarcinoma 43
 Squamous cell carcinoma 19
 Unclassified NSCLC 3
Tumor opacity (n), pure GGN/part solid GGN/solid 2/18/45
Location (n), central/peripheral 1/64
Location (n), left/right 24/41
Location (n), upper lobe/middle lobe/lower lobe 37/1/27
Prescribed dose (n)
 48 Gy (isocenter) 41
 60 Gy (isocenter) 6
 48 Gy (D95) 18
Table 2 Local control and  survival rates after  stereotactic 
body radiation therapy
Parameter 1-year 3-year 5-year
Local control (%) 98.4 90.1 87.4
Cancer-specific survival (%) 98.4 93.7 83.5
Progression-free survival (%) 81.0 58.9 38.2
Overall survival (%) 88.9 68.3 47.5
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and 0.026; hazard ratio (HR) = 1.42, 0.27, 2.65, and 2.59, 
respectively]. In the multivariate analysis, only operabil-
ity was confirmed to be an independent predictor of a 
high PFS (p = 0.047, HR = 0.34). The results of the univar-
iate and multivariate analyses of factors associated with 
OS are shown in Table 3. In the univariate analysis, sex, 
ECOG PS, operability, tumor appearance, and tumor his-
tology were the predictors of OS (p = 0.047, 0.023, 0.008, 
0.005, and 0.001; HR = 0.38, 1.53, 0.20, 5.52, and 3.14, 
respectively). In the multivariate analysis, operability and 
tumor appearance were confirmed to be the independent 
predictors of OS (p = 0.03 and 0.04; HR = 0.25 and 5.76, 
respectively).
Toxicity
All patients successfully completed SBRT. We observed 
grade 3 radiation pneumonitis (RP) in two patients 
(3.1%), while grade 5 RP was observed in one patient 
(1.6%). Both patients who developed grade 3 RP had been 
judged medically inoperable. Grade 3 RP occurred at 2.8 
a b
c d
Fig. 1 Local control and survival rates after stereotactic body radiotherapy. (a) Local control, (b) cancer-specific survival, (c) progression-free survival, 
and (d) overall survival
Fig. 2 Kaplan–Meier curves of overall survival for medically operable 
and medically inoperable patients. Medically operable patients are 
represented by the solid line; medically inoperable patients are 
represented by the dotted line
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and 3.6 months after completing SBRT. The patient who 
developed grade 5 RP had been judged medically inop-
erable. SBRT was performed twice for bilateral lesions 
in the lower lobes. The patient died of respiratory fail-
ure 3.8  months after completing the second course of 
SBRT. The data pertaining to lung-related comorbidity, 
tumor location, and dosimetry of patients who devel-
oped grade ≥ 3 RP are presented in Table  4. Except for 
RP, other grade ≥ 3 adverse events such as rib fracture, 
esophageal stenosis, tracheobronchial stenosis, neuropa-
thy, and hemorrhage were not reported.
Discussion
This study confirms that SBRT is associated with high 
LC rates, acceptable OS rates, and low toxicity rates 
in elderly patients aged ≥ 80  years with pathologically 
proven NSCLC.
Table 3 Univariate and multivariate analyses of overall survival
* p < 0.05; **p < 0.01
BMI, body mass index; CI, confidence interval; D95, dose covering 95% of the PTV; ECOG, Eastern Cooperative Oncology Group; GGN, ground-glass nodule; GOLD, 
Global Initiative for Chronic Obstructive Lung Disease; FEV, forced expiratory volume; HR, hazard ratio; ITV, internal target volume; NSCLC, non-small cell lung cancer; 
PS, performance status; PTV, planning target volume; SCC, squamous cell carcinoma
† These variables have missing values
Characteristic n Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Age (years) – 1.07 0.95–1.21 0.24 – – –
Sex
 Male 45 1.00 – – 1.00 – –
 Female 19 0.38 0.15–0.99 0.04* 1.85 0.48–7.18 0.38
BMI (kg/m2) – 0.97 0.86–1.10 0.65 – – –
ECOG PS – 1.53 1.06–2.21 0.02* 1.26 0.84–1.89 0.26
GOLD stage†
 Normal + I 42 1.00 – – – – –
 II + III 17 1.50 0.72–3.11 0.28 – – –
FEV1.0 (L) † 0.46 0.20–1.06 0.07 – – –
History of lung operation
 No 50 1.00 – – – – –
 Yes 14 1.49 0.68–3.24 0.32 – – –
Charlson Comorbidity Index – 1.09 0.87–1.37 0.45 – – –
Operable
 No 48 1.00 – – 1.00 – –
 Yes 16 0.20 0.06–0.66 0.008** 0.25 0.07–0.86 0.03*
Tumor diameter (cm) 0.99 0.64–1.52 0.96 – – –
ITV (mL) – 1.00 0.97–1.03 0.96 – – –
PTV (mL) – 1.00 0.98–1.01 0.83 – – –
T stage – 1.16 0.88–1.53 0.29 – – –
Histology
 Adenocarcinoma 43 1.00 – – 1.00 – –
 SCC + NSCLC 22 3.14 1.56–6.31 0.001** 1.97 0.95–4.10 0.07
Tumor appearance
 Pure GGN + part-solid GGN 20 1.00 – – 1.00 – –
 Solid 45 5.52 1.68–18.14 0.005** 5.76 1.05–31.71 0.04*
Total dose (Gy)
 48 59 1.00 – – – – –
 60 6 0.94 0.83–1.06 0.29 – – –
Prescribed dose
 Isocenter 47 1.00 – – – – –
 D95 18 0.48 0.14–1.64 0.24 – – –
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Previous studies have shown that SBRT can achieve 
excellent therapeutic effects with only mild adverse 
events [6–11, 13, 14, 20]. SBRT is less invasive than surgi-
cal resection and is performed for early-stage NSCLC in 
medically inoperable patients [8, 14]. While surgery is the 
standard treatment for patients with early-stage NSCLC 
who can tolerate surgical resection [4], elderly patients 
aged ≥ 80  years are often judged medically inoperable 
owing to comorbidities. Even when elderly patients are 
judged medically operable, surgical resection has been 
related to high morbidity and mortality rates [5, 20–22]. 
The postsurgical morbidity and mortality rates of elderly 
patients have been reported to be 18.0–45.0% and 0.0–
15.0%, respectively [21, 23]. Compared with surgical 
resection, SBRT is associated with a lower morbidity rate 
of 1.3–5.4% in elderly patients [23–25]. Furthermore, the 
frequency of grade 5 SBRT-related toxicities in elderly 
patients has been reported to be 0.0–2.1% [10, 11, 13, 14]. 
In the present study, two patients (3.1%) developed grade 
3 RP, and one patient developed grade 5 RP (1.6%). In 
the patient with grade 5 RP, non-breath-hold SBRT was 
performed twice for bilateral lesions in the lower lobes. 
Therefore, it is possible that the irradiated lung dose 
could have increased unexpectedly.
There are a few reports on the treatment outcomes 
of SBRT in elderly patients with pathologically proven 
NSCLC. Shu et  al. [18] reported the outcomes of 68 
patients aged ≥ 75  years with pathologically proven 
early-stage (T1-3N0M0) NSCLC. The 1-, 3-, and 5-year 
LC rates were 95.6%, 88.9%, and 85.6%, respectively. 
The 1-, 3-, and 5-year OS rates were 92.6%, 77.2%, and 
59.1%, respectively. In this study, the 1-, 3-, and 5-year 
LC and OS rates were 98.4%, 90.1%, and 87.4%, and 
88.9%, 68.3%, and 47.5%, respectively. Although our OS 
rates may appear slightly worse, we postulate that these 
differences may be owing to the age of the patients 
because our LC rates were almost identical to those of 
the previous report [18]. Kreinbrink et al. [13], Takeda 
et  al. [14], and Bei et  al. [15] reported the treatment 
outcomes of elderly patients aged ≥ 80 years with early-
stage NSCLC. In the study by Kreinbrink et  al. [13], 
the 1- and 2-year LC and OS rates were 100.0% and 
92.3%, and 83.5% and 59.2%, respectively. In the study 
by Takeda et al. [14], the 1- and 3-year LC and OS rates 
were 94.4% and 82.3%, and 95.0% and 53.7%, respec-
tively. In the study by Bei et al. [15], the 3-year OS rate 
was 65.3% [15]. Our results are comparable to those of 
the previous three studies. However, the previous stud-
ies included some lesions that had not been pathologi-
cally confirmed as NSCLC. Pulmonary nodules can be 
benign as well as malignant [16, 17]. Yang et al. reported 
the diagnostic accuracy of percutaneous transthoracic 
needle biopsy in the evaluation of solitary pulmonary 
nodules [16]. Among 311 nodules, 78 (25.1%) nodules, 
including organized pneumonia, tuberculosis, scleros-
ing hemangioma, hamartoma, and aspergillosis, were 
benign. SBRT for benign lesions is contraindicated and, 
to some extent, can affect treatment outcomes. Because 
local recurrence and metastasis are not observed in a 
benign disease, LC and PFS may be higher than those 
in cases with pathologically diagnosed lung cancer. 
Therefore, it is desirable to make a definitive patho-
logical diagnosis before cancer treatment. Because all 
SBRT-treated lesions in this study had been diagnosed 
as NSCLC, our treatment outcomes are more reliable. 
To the best of our knowledge, this is the first study to 
include only patients aged ≥ 80  years with pathologi-
cally proven NSCLC.
There were no predictors of higher LC in this study. 
Previous studies showed that the biologically effec-
tive D95 was significantly correlated with the LC rate 
[26, 27]. However, there was no significant difference 
between the prescribed doses (D95 vs. isocenter) in 
this study. The reason for this difference may be owing 
to the small sample size. Kimura et  al. are conducting 
a nationwide clinical trial on dose escalation for SBRT 
Table 4 Lung-related comorbidity, tumor location, and dosimetric data of patients with radiation pneumonitis ≥ grade 3
FEV, forced expiratory volume; GOLD, Global Initiative for Chronic Obstructive Lung Disease; MLD, mean lung dose; PTV, planning target volume; RP, radiation 
pneumonitis; V20, volume receiving at least 20 Gy
Patient number 1 2 3
Adverse event and grade RP grade 3 RP grade 3 RP grade 5
FEV1.0 (L) 2.2 1.2 1.3
GOLD stage 0 1 2
History of lung operation No No No
Tumor location Right lower lobe Right lower lobe Bilateral lower lobe
PTV (mL) 85.0 110.6 32.4/59.0
Lung V20 (%) 8.4 16.2 18.3
MLD (Gy) 6.0 8.8 10.9
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[28]. This study is expected to reveal whether dose 
escalation is also beneficial in elderly patients.
In the present study, we found operability to be an 
independent predictor of good OS. Takeda et  al. [14] 
reported that the 3-year OS rates for operable and 
inoperable patients were 58.1% and 48.3%, respectively. 
Therefore, operability turned out to be a predictor of 
good OS after SBRT in elderly patients. Bei et  al. [15] 
also demonstrated that operability was a predictor 
of good OS in multivariate analysis. Similarly, in our 
study, the 3-year OS rates for operable and inoper-
able patients were 79.4% and 64.7%, respectively, and 
operability was a significant prognostic factor in mul-
tivariate analysis (p = 0.03). Our results are compara-
ble with those of the previous reports that have shown 
that medically operable patients have better prognosis. 
We initially considered that inoperable patients might 
have a shorter life expectancy than operable patients 
because inoperable patients had poor respiratory func-
tion, many comorbidities, or a poor general condition. 
Nagata et  al. [8] reported that the 3-year OS rates for 
operable and inoperable patients in the Japan Clini-
cal Oncology Group 0403 trial were 68.3% and 63.7%, 
respectively, and there is no difference in terms of OS 
between the two groups. In their study, less than one-
third of the patients were aged > 81  years, and the dif-
ferences in patients’ age may be the cause of these 
varying results. In elderly patients, operability may 
have a more pronounced effect on OS than in younger 
patients. However, further research is warranted.
Wang et al. showed that CT appearance was a signifi-
cant prognostic factor for OS in patients with early-stage 
lung cancer who underwent surgery, with the worst 
prognosis for solid tumors [29]. Solid nodules were also 
a predictor of poor OS in our study. However, no reason-
able interpretation of the OS data can be made because 
solid nodules were not a predictor of PFS in multivariate 
analysis. Since CT appearance is a significant prognostic 
factor for PFS in univariate analysis, this result may be 
owing to the small sample size of this study.
Our study has a few limitations. First, this was a ret-
rospective, single-center study with a small sample size. 
Second, we did not use a quantitative model for judg-
ing operability. Instead, operability was judged based on 
the consensus of several thoracic surgeons or respira-
tory physicians. Nevertheless, the treatment outcomes 
showed that SBRT achieved high LC rates and acceptable 
OS rates, even in elderly patients aged ≥ 80  years with 
pathologically proven NSCLC. In addition, our results 
indicated that medically operable patients had better 
treatment outcomes. We believe that our findings may 
help select an appropriate treatment strategy for patients 
aged ≥ 80 years with NSCLC.
Conclusions
We reviewed treatment outcomes of SBRT for elderly 
patients aged ≥ 80  years with pathologically proven 
NSCLC. Our findings suggest that SBRT is beneficial for 
elderly patients with early-stage NSCLC for whom it is 
difficult to determine the optimal treatment strategy.
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